KBC Group NV Acquires 978 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

KBC Group NV lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 45.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,135 shares of the company’s stock after buying an additional 978 shares during the quarter. KBC Group NV’s holdings in Dyne Therapeutics were worth $74,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in Dyne Therapeutics in the 3rd quarter worth $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the 3rd quarter worth $36,000. US Bancorp DE grew its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after acquiring an additional 1,212 shares during the last quarter. Values First Advisors Inc. bought a new stake in Dyne Therapeutics in the 3rd quarter worth $62,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the sale, the director now owns 15,962 shares of the company’s stock, valued at $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,071 shares of company stock valued at $606,476. Insiders own 20.77% of the company’s stock.

Analysts Set New Price Targets

DYN has been the subject of several research analyst reports. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Finally, Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.91.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $15.37 on Monday. The stock has a market cap of $1.56 billion, a P/E ratio of -4.32 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1 year low of $13.23 and a 1 year high of $47.45. The firm has a 50-day moving average of $20.94 and a 200 day moving average of $30.57.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.